Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab versus endoscopic medial wall orbital decompression for dysthyroid optic neuropathy
ChiCTR2600136037Phase 4Completed
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of teprotumumab in Graves Orbitopathy (GO) and dysthyroid optic neuropathy (DON) (2 arms), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoints: Change in best-corrected visual acuity and Change in visual field defect. Started Sep 2026; status: completed.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)dysthyroid optic neuropathy (DON)
Beyond the preview
Go deeper on ChiCTR2600136037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600136037.